The overall survival benefit seen with addition of bevacizumab to cisplatin/pemetrexed in patients with mesothelioma is practice-changing, according to Naiyer Rizvi, MD. The panelists discuss the data presented at ASCO 2015. View Now >>
Morie A. Gertz, MD; Rafael Fonseca, MD; Noopur Suresh Raje, MD; and Jatin J. Shah, MD, explain the role of the immunomodulatory drug, pomalidomide, in the management of multiple myeloma. View Now >>
Featured Program
Giants of Cancer Care
The OncLive News Network updates viewers on breaking news, clinical trial results, FDA approvals, and offers an inside look into leading cancer centers and clinical trials. View Now >>
Highlights from the 2014 ASH Annual Meeting
Laura Jones recaps major findings from the 2015 ASCO Annual Meeting, including phase III findings for new treatments in melanoma, chronic lymphocytic leukemia, lung cancer, breast cancer, and multiple myeloma.
View Now

Most Popular Right Now